Using system biology and bioinformatics to identify the influences of COVID-19 co-infection with influenza virus on COPD
- PMID: 37221323
- PMCID: PMC10205564
- DOI: 10.1007/s10142-023-01091-3
Using system biology and bioinformatics to identify the influences of COVID-19 co-infection with influenza virus on COPD
Abstract
Coronavirus disease 2019 (COVID-19) has speedily increased mortality globally. Although they are risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), less is known about the common molecular mechanisms behind COVID-19, influenza virus A (IAV), and chronic obstructive pulmonary disease (COPD). This research used bioinformatics and systems biology to find possible medications for treating COVID-19, IAV, and COPD via identifying differentially expressed genes (DEGs) from gene expression datasets (GSE171110, GSE76925, GSE106986, and GSE185576). A total of 78 DEGs were subjected to functional enrichment, pathway analysis, protein-protein interaction (PPI) network construct, hub gene extraction, and other potentially relevant disorders. Then, DEGs were discovered in networks including transcription factor (TF)-gene connections, protein-drug interactions, and DEG-microRNA (miRNA) coregulatory networks by using NetworkAnalyst. The top 12 hub genes were MPO, MMP9, CD8A, HP, ELANE, CD5, CR2, PLA2G7, PIK3R1, SLAMF1, PEX3, and TNFRSF17. We found that 44 TFs-genes, as well as 118 miRNAs, are directly linked to hub genes. Additionally, we searched the Drug Signatures Database (DSigDB) and identified 10 drugs that could potentially treat COVID-19, IAV, and COPD. Therefore, we evaluated the top 12 hub genes that could be promising DEGs for targeted therapy for SARS-CoV-2 and identified several prospective medications that may benefit COPD patients with COVID-19 and IAV co-infection.
Keywords: COPD; COVID-19; Differentially expressed genes; Drug molecule; Hub genes; Influenza viruses.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures








References
-
- Abdel-Aziz MI, Kermani NZ, Neerincx AH, Vijverberg SJH, Guo Y, Howarth P, Dahlen SE, Djukanovic R, Sterk PJ, Kraneveld AD, Maitland-van der Zee AH, Chung KF, Adcock IM, On behalf the UBC Association of endopeptidases, involved in SARS-CoV-2 infection, with microbial aggravation in sputum of severe asthma. Allergy. 2021;76:1917–1921. doi: 10.1111/all.14731. - DOI - PubMed
-
- Arguni E, Supriyati E, Hakim MS, Daniwijaya EW, Makrufardi F, Rahayu A, Rovik A, Saraswati U, Oktoviani FN, Prastiwi N, Nuryastuti T, Wibawa T, Haryana SM. Co-infection of SARS-CoV-2 with other viral respiratory pathogens in Yogyakarta, Indonesia: a cross-sectional study. Ann Med Surg (Lond) 2022;77:103676. doi: 10.1016/j.amsu.2022.103676. - DOI - PMC - PubMed
-
- Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, Wang X, Huang Z, Sun X, Zhang Z, Dong L, Liu Q, Zheng Y, Niu D, Xiang M, Song K, Ye J, Zheng W, Tang Z, Tang M, Zhou Y, Shen C, Dai M, Zhou L, Chen Y, Yan H, Lan K, Xu K. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31:395–403. doi: 10.1038/s41422-021-00473-1. - DOI - PMC - PubMed
-
- Bankar R, Suvarna K, Ghantasala S, Banerjee A, Biswas D, Choudhury M, Palanivel V, Salkar A, Verma A, Singh A, Mukherjee A, Pai MGJ, Roy J, Srivastava A, Badaya A, Agrawal S, Shrivastav O, Shastri J, Srivastava S. Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19. iScience. 2021;24:102135. doi: 10.1016/j.isci.2021.102135. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous